MX2019010837A - Conjugado biodegradable de farmaco-polimero. - Google Patents

Conjugado biodegradable de farmaco-polimero.

Info

Publication number
MX2019010837A
MX2019010837A MX2019010837A MX2019010837A MX2019010837A MX 2019010837 A MX2019010837 A MX 2019010837A MX 2019010837 A MX2019010837 A MX 2019010837A MX 2019010837 A MX2019010837 A MX 2019010837A MX 2019010837 A MX2019010837 A MX 2019010837A
Authority
MX
Mexico
Prior art keywords
functional group
formula
group
terminal functional
instance
Prior art date
Application number
MX2019010837A
Other languages
English (en)
Spanish (es)
Inventor
John Tait Russell
Craig Donohue Andrew
Marina D'souza Asha
Sulistio Adrian
Lonsdale Birkett Stephen
Naylor Alan
Vittoria SCULLINO Carmen
Man Yee Ng Sarah
Valade David
Watling Jason
Original Assignee
Polyactiva Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/458,546 external-priority patent/US10113033B2/en
Priority claimed from AU2017900888A external-priority patent/AU2017900888A0/en
Application filed by Polyactiva Pty Ltd filed Critical Polyactiva Pty Ltd
Publication of MX2019010837A publication Critical patent/MX2019010837A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595Polyamides, e.g. nylon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/08Polyhydrazides; Polytriazoles; Polyaminotriazoles; Polyoxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019010837A 2017-03-14 2018-03-14 Conjugado biodegradable de farmaco-polimero. MX2019010837A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/458,546 US10113033B2 (en) 2013-03-08 2017-03-14 Polymer conjugate for delivery of a bioactive agent
AU2017900888A AU2017900888A0 (en) 2017-03-14 Biodegradable drug-polymer conjugate
PCT/AU2018/050234 WO2018165711A1 (en) 2017-03-14 2018-03-14 Biodegradable drug-polymer conjugate

Publications (1)

Publication Number Publication Date
MX2019010837A true MX2019010837A (es) 2019-12-19

Family

ID=63521659

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010837A MX2019010837A (es) 2017-03-14 2018-03-14 Conjugado biodegradable de farmaco-polimero.
MX2019010904A MX2019010904A (es) 2017-03-14 2018-03-14 Conjugado de farmaco-polimero.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010904A MX2019010904A (es) 2017-03-14 2018-03-14 Conjugado de farmaco-polimero.

Country Status (14)

Country Link
US (2) US11787906B2 (https=)
EP (2) EP3595670A4 (https=)
JP (2) JP7355649B2 (https=)
KR (2) KR102642432B1 (https=)
CN (4) CN110461336A (https=)
AU (2) AU2018233158B2 (https=)
CA (1) CA3054084A1 (https=)
CL (1) CL2019002600A1 (https=)
IL (2) IL269321B (https=)
MX (2) MX2019010837A (https=)
NZ (2) NZ756626A (https=)
SG (2) SG11201907956UA (https=)
WO (2) WO2018165710A1 (https=)
ZA (2) ZA201905589B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
CA3154867A1 (en) * 2019-09-19 2021-03-25 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
MY155629A (en) 2008-10-10 2015-11-13 Polyactiva Pty Ltd Biodegradable polymer-bioactive moiety conjugates
SI2340271T1 (sl) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
US8535655B2 (en) * 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20120130045A1 (en) 2009-06-01 2012-05-24 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
WO2012139164A1 (en) * 2011-04-12 2012-10-18 Polyactiva Pty Ltd Polymer conjugated prostaglandin analogues
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
MY190370A (en) * 2012-06-26 2022-04-18 Polyactiva Pty Ltd Polymer-nsaid conjugate
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
DK2964224T3 (en) * 2013-03-08 2024-10-14 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate

Also Published As

Publication number Publication date
EP3595728A1 (en) 2020-01-22
WO2018165711A1 (en) 2018-09-20
JP2020510690A (ja) 2020-04-09
JP2020510692A (ja) 2020-04-09
WO2018165710A1 (en) 2018-09-20
JP7204661B2 (ja) 2023-01-16
IL269323A (en) 2019-11-28
CA3054084A1 (en) 2018-09-20
BR112019018914A2 (pt) 2020-06-30
IL269321B (en) 2022-07-01
KR102642432B1 (ko) 2024-02-28
CN120919337A (zh) 2025-11-11
AU2018233158A1 (en) 2019-09-12
KR20190124243A (ko) 2019-11-04
CN110662561A (zh) 2020-01-07
ZA201906133B (en) 2021-04-28
CN110461336A (zh) 2019-11-15
US11787906B2 (en) 2023-10-17
CA3054328A1 (en) 2018-09-20
US20240247106A1 (en) 2024-07-25
AU2018233159B8 (en) 2024-08-01
AU2018233159A1 (en) 2019-09-12
AU2018233159B2 (en) 2024-05-02
US12503553B2 (en) 2025-12-23
CL2019002600A1 (es) 2020-04-03
EP3595670A4 (en) 2021-05-12
KR20190123776A (ko) 2019-11-01
CN120919336A (zh) 2025-11-11
IL269323B (en) 2022-07-01
IL269321A (en) 2019-11-28
MX2019010904A (es) 2019-12-09
SG11201907956UA (en) 2019-09-27
SG11201907931WA (en) 2019-09-27
JP7355649B2 (ja) 2023-10-03
KR102642433B1 (ko) 2024-02-28
AU2018233158B2 (en) 2024-04-11
NZ756626A (en) 2022-10-28
ZA201905589B (en) 2020-07-29
EP3595670A1 (en) 2020-01-22
NZ757356A (en) 2022-10-28
AU2018233159C1 (en) 2025-01-02
AU2018233159A8 (en) 2024-08-01
US20200123322A1 (en) 2020-04-23
EP3595728A4 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
MX2019010837A (es) Conjugado biodegradable de farmaco-polimero.
MX2015001509A (es) Poliesteres.
RU2007115075A (ru) Новый блок-сополимер, мицеллярный препарат и противораковое средство, включающее мицеллярный препарат в качестве активного ингредиента
CO6220850A2 (es) Mezclas de fertilizante-polimero que inhiben la nitrificacion en los suelos
PE20141219A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol y su uso
TW200626691A (en) Acrylic pressure-sensitive adhesive composition with good re-workability, adhesive sheet, and method of preparing the sheet
MX391071B (es) Conjugados de un resto de il-7 y un polímero.
EA201000747A1 (ru) Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
RU2012144848A (ru) Быстро растворяющиеся системы, освобождающие лекарственные препараты
AR060295A1 (es) Uso de surfactantes sililados organomodificados resistentes a la hidrolisis
MX377120B (es) Composicion curable fotocromatica, producto curado de la misma y laminado que incluye el producto curado.
ATE518896T1 (de) Kammpolymere enthaltende wirkstoffformulierungen
WO2008124735A3 (en) Multi-functional polyglutamate drug carriers
MX2009005623A (es) Copolimeros de cepillo.
MX351429B (es) Materiales dentales basados en monómeros con propiedades de despegado según sea necesario.
MX2022001161A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos.
MX2016010140A (es) Nuevos eteres de celulosa esterificados de alto peso molecular y homogeneidad.
PE20171510A1 (es) Copolimeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2
AR093299A1 (es) Adyuvantes adherentes de poliamida y poliimida
AR109686A1 (es) Selladoras de esfera degradables con características de solubilidad
BR112018004260A2 (pt) composição polimerizável, polimerizado e artigo óptico
CL2023000460A1 (es) Envase soluble en agua que contiene colorante y procedimiento para preparar solución acuosa coloreada
WO2013054298A3 (en) Modified polyethylene glycols and their supramolecular complexes with biologically active macromolecules
AR065930A1 (es) Conjugado wortmannina-rapalogo y sus usos
CO2021002726A2 (es) Copolímeros de óxido de dimetilsiloxano-alquileno